Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Guinness Global Innovators Dr Ian Mortimer, CFA | “Medtronic (+16.3%, USD) was the portfolio's best-performing company during the month. The leading medical device company released strong Q2 earnings, beating on the top and bottom lines as well as raising full-year organic growth expectations to 5.5% (up from 5% previously). The clear stand-out in their portfolio at present is the ongoing strong performance of Cardiac Ablation Solutions (CAS), a business which grew 71% year-on-year on the strength of the pulsed field ablation (PFA) portfolio and added around 180 basis points of organic growth to top line. The CAS outlook remains healthy given ongoing rapid adoption, positive regulatory approvals and strong physician demand for safer, faster atrial fibrillation procedures. BSD Analysis: Medtronic's moat is installed base inertia across hospitals and clinicians. Devices become workflows, and workflows become switching costs. Recurring consumables stabilize revenue even when procedure volumes dip. Innovation pace has lagged nimbler competitors, slowly narrowing the moat. Pricing pressure from hospitals is constant and structural. Scale still matters in regulatory navigation and distribution. The company trades on reliability rather than excitement. Execution consistency determines whether the moat holds or erodes. Medtronic is a wide moat slowly challenged by speed.” | BULL | Q4 2025 Dec 1, 2025 | View Pitch |
Artisan Focus Fund Christopher Smith | “Medtronic is cited as an example of a potential value trap that appears optically cheap at 15X EPS but fails to generate an ROIC above its cost of capital. Over time, its slow growth rate and value destruction cause its true valuation to become more expensive than high-quality growth companies.” | BEAR | Q2 2024 Jun 30, 2024 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
